Related Experiment Videos
Restoration of tumour suppressor gene expression for cancer
1Department of Thoracic and Cardiovascular Surgery, The University of Texas, MD Anderson Cancer Center, Houston 77030, USA.
Abstract:
Gene therapy has the potential to provide cancer treatments based on novel mechanisms of action with potentially low toxicities. This therapy may provide more effective control of loco-regional recurrence in diseases such as non-small cell lung cancer (NSCLC), as well as systemic control of micrometastases. Despite current limitations, retroviral and adenoviral vectors can in certain circumstances provide an effective means of delivering therapeutic genes to tumour cells. Although multiple genes are involved in the process of carcinogenesis, mutations of the p53 gene are the most frequent abnormality identified in human tumours. Pre-clinical studies both in vitro and in vivo have shown that restoration of p53 function can induce apoptosis in cancer cells. Phase I clinical trials now show that p53 gene replacement therapy is feasible and safe using both retroviral and adenoviral vectors, and that it induces tumour regression in patients with advanced NSCLC and recurrent head and neck cancer. Other pre-clinical studies indicate that gene therapy may have useful synergy with cytotoxic and radiation therapy. This paper describes the different gene therapy strategies under investigation and the pre-clinical data that provides a rationale for the gene replacement approach, reviews clinical trial data and presents novel ideas for improving current vectors and gene delivery to tumours.
Insights
Gene therapy, particularly p53 gene replacement, shows promise for treating non-small cell lung cancer (NSCLC) and other cancers. Clinical trials indicate feasibility, safety, and tumor regression, suggesting a new therapeutic avenue.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Gene therapy offers novel cancer treatment mechanisms with potentially low toxicity.
- Non-small cell lung cancer (NSCLC) and other malignancies present challenges in loco-regional recurrence and systemic metastasis control.
- p53 gene mutations are frequent in human tumors, making p53 restoration a target for cancer therapy.
Purpose of the Study:
- To review gene therapy strategies for cancer treatment, focusing on gene replacement approaches.
- To present pre-clinical and clinical data supporting the efficacy and safety of p53 gene therapy.
- To explore novel vector and gene delivery improvements for enhanced tumor targeting.
Main Methods:
- Review of pre-clinical in vitro and in vivo studies on p53 gene function restoration.
- Analysis of Phase I clinical trial data for p53 gene replacement therapy in NSCLC and head and neck cancers.
- Examination of potential synergistic effects of gene therapy with conventional treatments like chemotherapy and radiation.
Main Results:
- Restoration of p53 function in cancer cells induces apoptosis.
- Phase I trials demonstrate the feasibility and safety of p53 gene replacement using retroviral and adenoviral vectors.
- Tumor regression observed in patients with advanced NSCLC and recurrent head and neck cancer.
Conclusions:
- p53 gene replacement therapy is a feasible and safe approach for treating specific cancers.
- Gene therapy, especially p53 restoration, holds potential for improved cancer control and synergy with existing therapies.
- Ongoing research aims to enhance gene delivery vectors for more effective tumor targeting.